Intended for US residents only

Grifols logo
  • Patient - CIDP
  • Patient - PIDD
  • HCP - PIDD

Important Safety Information

Prescribing Information

Grifols logo
'Gamunex-C' logo 'Gamunex-C' logo
  • CIDP
    • Pathophysiology
    • Efficacy
  • Product Purity and
    Characteristics
  • Dosing and
    Administration
    • Gamunex Connexions
    • Office Resources
    • Clinical Resources
Go to PIDD Request a rep
  • Patient - CIDP
  • Patient - PIDD
  • HCP - PIDD
  • CIDP
  • Efficacy and
    Tolerability
    • Pathophysiology
    • Efficacy
  • Product Purity and
    Characteristics
  • Dosing and
    Administration
  • Support and
    Resources
    • Gamunex Connexions
    • Office Resources
    • Clinical Resources
Go to PIDD Request a rep
Newest

Sort by

Newest
Oldest
Title (A-Z)
Title (Z-A)
Done

Showing 10 search results

What is GAMUNEX-C for CIDP?

Trusted neuroprotection from inflammation in CIDP with >87% of responders relapse free in the extension phase of the ICE study.

What is GAMUNEX-C for CIDP?

Trusted neuroprotection from inflammation in CIDP with >87% of responders relapse free in the extension phase of the ICE study.

What is maximum purity of IgG?

Unique caprylate/chromatography fractionation and purification process with maximum percentage of IgG ≥98%

What is maximum purity of IgG?

Unique caprylate/chromatography fractionation and purification process with maximum percentage of IgG ≥98%

Dosing and Administration for GAMUNEX-C

The ICE study established the standard for dosing IVIG in CIDP with 87% of loading dose courses given over 2 days.

Dosing and Administration for GAMUNEX-C

The ICE study established the standard for dosing IVIG in CIDP with 87% of loading dose courses given over 2 days.

The pathophysiology of CIDP

Early detection is critical as the patient can experience secondary axonal loss, resulting in potentially irreversible nerve damage and permanent disability.

The pathophysiology of CIDP

Early detection is critical as the patient can experience secondary axonal loss, resulting in potentially irreversible nerve damage and permanent disability.

Chronic inflammatory demyelinating polyneuropathy is complex

Several mechanisms play a role in the pathophysiology of CIDP, including inflammation, demyelination, and axonal damage.

Chronic inflammatory demyelinating polyneuropathy is complex

Several mechanisms play a role in the pathophysiology of CIDP, including inflammation, demyelination, and axonal damage.

Gamunex Connexions Support Program for CIDP Patients

Gamunex Connexions offers financial help for your patients and administrative help for your office.

Gamunex Connexions Support Program for CIDP Patients

Gamunex Connexions offers financial help for your patients and administrative help for your office.

Office Resources and Support for CIDP

Coverage authorization, billing, coding, reimbursement, and storage and handling of GAMUNEX-C

Office Resources and Support for CIDP

Coverage authorization, billing, coding, reimbursement, and storage and handling of GAMUNEX-C

Fighting Inflammation

Several mechanisms play a role in the pathophysiology of CIDP, including inflammation, demyelination, and axonal damage.

Fighting Inflammation

Several mechanisms play a role in the pathophysiology of CIDP, including inflammation, demyelination, and axonal damage.

Efficacy of GAMUNEX-C

GAMUNEX-C fights inflammation, has proven tolerability, and reduces the impact of CIDP on patients' lives.

Efficacy of GAMUNEX-C

GAMUNEX-C fights inflammation, has proven tolerability, and reduces the impact of CIDP on patients' lives.

Dosing and Administration for GAMUNEX-C

The ICE study established the standard for dosing IVIG in CIDP with 87% of loading dose courses given over 2 days.

Dosing and Administration for GAMUNEX-C

The ICE study established the standard for dosing IVIG in CIDP with 87% of loading dose courses given over 2 days.

'Gamunex-C' logo 'Gamunex-C' logo

CIDP

Efficacy and Tolerability

Efficacy and Tolerability

  • Pathophysiology
  • Efficacy

Product Purity and Characteristics

Dosing and Administration

Support and Resources

Support and Resources

  • Gamunex Connexions
  • Office Resources
  • Clinical Resources
Grifols logo
  • Cookies Settings

  • Cookies Policy

  • Go to patient site

  • Privacy Notice

  • About Grifols

  • Contact us


2410 Lillyvale Ave
Los Angeles, CA 90032-3514

  • 1-888-GRIFOLS (1-888-474-3657)
  • customer.service@grifols.com
  • https://www.grifols.com

© 2023 Grifols. All rights reserved

US-GXC-2300138

Welcome!
Learn more about GAMUNEX-C

I am a -

Healthcare Professional Patient or Caregiver

Are you sure you want to leave our site?

Please be advised that Grifols has no control over the content or presentation of the site you are about to view.

Please select “Continue” if you wish to be taken to this third-party website.

Continue Cancel